XGN Price / Book | EXAGEN INC.

EXAGEN INC. Price/Book Ratio

The price-to-book (P/B) ratio compares what the stock market says a company is worth with what the company's own books say it is worth. It is market capitalization divided by shareholder equity, the book value left after subtracting liabilities from assets, and the table shows both amounts. A ratio of 1.0 means market value equals book value; a higher ratio means investors value the company above its net assets, often for brands, software or expected growth the books do not record. A negative ratio means equity is negative. Each point uses the filed share count and the last closing price on or before the equity's reporting date, never today's price.

EXAGEN INC. price/book ratio for the quarter ending 2026-06-30 was 9.21, a 26.42% increase year-over-year.
EXAGEN INC. price/book ratio for the quarter ending 2026-03-31 was 5.04, a 49.92% decline year-over-year.
EXAGEN INC. price/book ratio for the quarter ending 2025-12-31 was 8, a 5.56% increase year-over-year.
EXAGEN INC. price/book ratio for the quarter ending 2025-09-30 was 13.68, a 225.08% increase year-over-year.
EXAGEN INC. price/book ratio for fiscal 2026 was 9.21.
EXAGEN INC. price/book ratio for fiscal 2025 was 8, a 5.56% increase from fiscal 2024.
EXAGEN INC. price/book ratio for fiscal 2024 was 7.58, a 407.20% increase from fiscal 2023.
EXAGEN INC. price/book ratio for fiscal 2023 was 1.49, a 59.78% increase from fiscal 2022.

Available history: 2019-09-30 to 2026-06-30
Data captured: 2026-06-30

Historical Price/Book Ratio

Date	Price/Book Ratio	Market capitalization	Shareholder equity
2026-06-30	9.21	$112.5M	$12.22M
2026-03-31	5.04	$72.75M	$14.43M
2025-12-31	8	$139.65M	$17.45M
2025-09-30	13.68	$248.06M	$18.14M
2025-06-30	7.28	$153.22M	$21.03M
2025-03-31	10.06	$64.44M	$6.4M
2024-12-31	7.58	$72.33M	$9.54M
2024-09-30	4.21	$54.14M	$12.87M
2024-06-30	1.8	$31.63M	$17.59M
2024-03-31	1.38	$27.54M	$19.99M
2023-12-31	1.49	$33.92M	$22.69M
2023-09-30	1.49	$40.98M	$27.5M
2023-06-30	1.53	$48.89M	$31.9M
2023-03-31	1.14	$40.89M	$35.94M
2022-12-31	0.94	$39.72M	$42.46M
2022-09-30	0.79	$44.19M	$56.19M
2022-06-30	1.49	$93.33M	$62.82M
2022-03-31	1.71	$130.34M	$76.16M
2021-12-31	2.21	$188M	$84.94M
2021-09-30	2.42	$219.83M	$90.8M
2021-06-30	2.51	$241.74M	$96.38M
2021-03-31	2.92	$296.2M	$101.47M
2020-12-31	3.99	$167.01M	$41.84M
2020-09-30	3.08	$137.15M	$44.47M
2020-06-30	3.28	$156.87M	$47.84M
2020-03-31	3.98	$201.28M	$50.54M
2019-12-31	5.73	$319.05M	$55.66M
2019-09-30	3.32	$194.55M	$58.65M

Annual Price/Book Ratio

Date	Price/Book Ratio	Market capitalization	Shareholder equity
2026-06-30	9.21	$112.5M	$12.22M
2025-12-31	8	$139.65M	$17.45M
2024-12-31	7.58	$72.33M	$9.54M
2023-12-31	1.49	$33.92M	$22.69M
2022-12-31	0.94	$39.72M	$42.46M
2021-12-31	2.21	$188M	$84.94M
2020-12-31	3.99	$167.01M	$41.84M
2019-12-31	5.73	$319.05M	$55.66M

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Freenome, Inc. (FRNM)	United States	$0.143B
BIODESIX INC (BDSX)	United States	$0.312B
SERA PROGNOSTICS, INC. (SERA)	United States	$0.062B	-5.75
AMERICAN SHARED HOSPITAL SERVICES (AMS)	United States	$0.010B	-5.64
Advanced Biomed Inc. (ADVB)		$0.009B
Aclarion, Inc. (ACON)	United States	$0.008B
BioNexus Gene Lab Corp (BGLC)		$0.004B
Fulgent Genetics, Inc. (FLGT)	United States	$0.593B	-6.70
Lumexa Imaging Holdings, Inc. (LMRI)	United States	$0.951B
CASTLE BIOSCIENCES INC (CSTL)	United States	$1.074B	-37.45